Glepaglutide, a Long-acting Glucagon-like Peptide-2 Analog, Reduces Parenteral Support in Patients with Short Bowel Syndrome: a Phase 3, Randomized, Controlled Trial.

Background And Aims: Glepaglutide is a long-acting GLP-2 analog developed to improve intestinal absorption in short bowel syndrome (SBS) patients. We conducted a trial to establish efficacy and safety of glepaglutide in reducing parenteral support (PS) needs in SBS patients with intestinal failure (IF).

Methods: In an international, placebo-controlled, randomized, parallel-group, double-blind, phase 3 trial, SBS-IF patients requiring PS ≥3 days/week were randomized 1:1:1 to 24 weeks of glepaglutide 10 mg twice-weekly (TW) or once-weekly (OW), or placebo.

OptimCLM: Optimizing clinical language models for predicting patient outcomes via knowledge distillation, pruning and quantization.

Background: Clinical Language Models (CLMs) possess the potential to reform traditional healthcare systems by aiding in clinical decision making and optimal resource utilization. They can enhance patient outcomes and help healthcare management through predictive clinical tasks. However, their real-world deployment is limited due to high computational cost at inference, in terms of both time and space complexity.

Effects of increasing fitness through exercise training on language comprehension in monolingual and bilingual older adults: a randomized controlled trial.

Exercise training has been proposed to counteract age-related cognitive decline through improvements in cardiorespiratory fitness (CRF hypothesis). Research has focused on cognitive domains like attention and processing speed, and one cross-sectional study reported a positive relationship between CRF and language production in older adults. In a randomized controlled trial, we investigated whether these benefits could extend to language comprehension in healthy older adults, and whether bilinguals, for whom language processing is more costly, would exhibit greater benefits than monolinguals.

Clinical and genetic characterization of a progressive RBL2-associated neurodevelopmental disorder.

Retinoblastoma (RB) proteins are highly conserved transcriptional regulators that play important roles during development by regulating cell-cycle gene expression. RBL2 dysfunction has been linked to a severe neurodevelopmental disorder. However, to date, clinical features have only been described in six individuals carrying five biallelic predicted loss of function (pLOF) variants.